Diclofenac is effective in treating post-operative pain1
The benefits of this medicine are greater than its risks.*2
Diclofenac has been used extensively in clinical practice for up to 50 years3
Diclofenac is effective in treating a wide variety of acute and painful inflammatory conditions1
*but there is a small risk of heart attack or strokes in patients taking systemic diclofenac regularly, especially at high doses (150 mg daily) and for long periods. If 1,000 patients at moderate risk took diclofenac for a year, there would be about 3 extra cases of heart attack among them, compared with patients not taking diclofenac.2
Our Products
References
Cataflam® 50mg Egyptian Drug Authority approved insert leaflet. Date of approval: 26/12/2024.
New safety advice for diclofenac. European Medicines Agency. Available at: https://www.ema.europa.eu/en/documents/referral/diclofenac-article-31-referral-new-safety- advice-diclofenac_en.pdf. Last accessed 14.5.2025
Fineschi G, Tamburrelli F.C, Francucci B.M, et al. Oral Diclofenac Dispersible Provides a Faster Onset of Analgesia than Intramuscular Ketorolac in the Treatment of Postoperative Pain. Clin. Drug Invest. 1997; 13 (1):1–7.
Approved by Egyptian Drug Authority: HF0082OA4733/082025. Invalidation date: 28/08/2027.
Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at: www.edaegypt.gov.eg
Image
|
HF0082OA4733/082025 |
Adverse Events Reporting We encourage using the following Electronic reporting tool for reporting into the safety database directly: |